Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

Chinese-U.S. hybrid MicuRx, founded by Vicuron veterans, has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.